real-time news and commentary for investors
Monday, Apr 15
The Supreme Court is due to hear arguments today on whether it's possible to patent isolated...
The Supreme Court is due to hear arguments today on whether it's possible to patent isolated human genes in a debate that encompasses the concept that IP can't cover "laws of nature." The case involves Myriad Genetics (MYGN), which holds two patents that allow it to genetically screen those at risk of breast or ovarian cancer. The impact of any ruling on the human-gene field will probably be limited, although it could have ramifications for the wider pharmaceuticals sector, agriculture, industrial microbiology and alternative fuels.